These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 9841322)

  • 21. Health supervision for children with sickle cell disease.
    Sox C
    Pediatrics; 2003 Mar; 111(3):710-1; author reply 710-1. PubMed ID: 12612266
    [No Abstract]   [Full Text] [Related]  

  • 22. Repeated transfusion for sickle cell.
    Cimons M
    Nat Med; 1997 Nov; 3(11):1184. PubMed ID: 9359680
    [No Abstract]   [Full Text] [Related]  

  • 23. High reticulocyte count is an independent risk factor for cerebrovascular disease in children with sickle cell anemia.
    Silva CM; Giovani P; Viana MB
    Pediatr Blood Cancer; 2011 Jan; 56(1):116-21. PubMed ID: 20949593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management issues for collaborative study in hematology. Sickle cell anemia, hemophilia, and ITP.
    Cohen A
    Clin Pediatr (Phila); 1987 Dec; 26(12):615-9. PubMed ID: 3315385
    [No Abstract]   [Full Text] [Related]  

  • 25. Cerebrovascular disease in symptomatic and asymptomatic patients with sickle cell anemia: screening with duplex transcranial Doppler US--correlation with MR imaging and MR angiography.
    Seibert JJ; Miller SF; Kirby RS; Becton DL; James CA; Glasier CM; Wilson AR; Kinder DL; Berry DH
    Radiology; 1993 Nov; 189(2):457-66. PubMed ID: 8105505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comment on improving transcranial Doppler ultrasonography screening in children with sickle cell anemia.
    Lewen MO; Kavanagh PL; Sobota AE
    Am J Hematol; 2017 Jun; 92(6):E121-E122. PubMed ID: 28335074
    [No Abstract]   [Full Text] [Related]  

  • 27. Acute and chronic management of children with sickle cell anemia and cerebrovascular occlusive crisis.
    Seeler RA; Royal JE
    IMJ Ill Med J; 1977 Apr; 151(4):267-9. PubMed ID: 14909
    [No Abstract]   [Full Text] [Related]  

  • 28. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood.
    Vichinsky EP; Earles A; Johnson RA; Hoag MS; Williams A; Lubin B
    N Engl J Med; 1990 Jun; 322(23):1617-21. PubMed ID: 2342522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transfusion therapy for cerebrovascular abnormalities in sickle cell disease.
    Russell MO; Goldberg HI; Reis L; Friedman S; Slater R; Reivich M; Schwartz E
    J Pediatr; 1976 Mar; 88(3):382-7. PubMed ID: 1245948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucose 6 phosphate dehydrogenase deficiency is not associated with cerebrovascular disease in children with sickle cell anemia.
    Rees DC; Lambert C; Cooper E; Bartram J; Goss D; Deane C; Thein SL
    Blood; 2009 Jul; 114(3):742-3; author reply 743-4. PubMed ID: 19608759
    [No Abstract]   [Full Text] [Related]  

  • 31. Impact of hydroxyurea on perioperative management and outcomes in children with sickle cell anemia.
    Hayashi M; Calatroni A; Herzberg B; Ross AK; Rice HE; Thornburg C
    J Pediatr Hematol Oncol; 2011 Oct; 33(7):487-90. PubMed ID: 21941139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention and management of strokes in patients with sickle cell disease.
    Abboud MR; Atweh GF
    Curr Hematol Rep; 2006 Mar; 5(1):15-22. PubMed ID: 16537042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebral blood flow in sickle cell cerebrovascular disease.
    Huttenlocher PR; Moohr JW; Johns L; Brown FD
    Pediatrics; 1984 May; 73(5):615-21. PubMed ID: 6718116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention.
    Kwiatkowski JL; Cohen AR; Garro J; Alvarez O; Nagasubramanian R; Sarnaik S; Thompson A; Woods GM; Schultz W; Mortier N; Lane P; Mueller B; Yovetich N; Ware RE;
    Am J Hematol; 2012 Feb; 87(2):221-3. PubMed ID: 22120913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
    Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J
    JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Indications and complications of transfusions in sickle cell disease.
    Smith-Whitley K; Thompson AA
    Pediatr Blood Cancer; 2012 Aug; 59(2):358-64. PubMed ID: 22566388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Risks associated with transfusions in sickle cell disease: delayed hemolytic transfusion reaction].
    Habibi A; Noizat-Pirenne F
    Rev Prat; 2014 Oct; 64(8):1128-9. PubMed ID: 25510142
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of a long-term transfusion regimen on sickle cell-related illnesses.
    Styles LA; Vichinsky E
    J Pediatr; 1994 Dec; 125(6 Pt 1):909-11. PubMed ID: 7996363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased blood requirements during long-term transfusion therapy for sickle cell disease.
    Cohen AR; Buchanan GR; Martin M; Ohene-Frempong K
    J Pediatr; 1991 Mar; 118(3):405-7. PubMed ID: 1999779
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy of transfusion therapy for one to two years in patients with sickle cell disease and cerebrovascular accidents.
    Wilimas J; Goff JR; Anderson HR; Langston JW; Thompson E
    J Pediatr; 1980 Feb; 96(2):205-8. PubMed ID: 7351580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.